Payment overview · 2025
General Payments
$495.66
22 reported records · 16 companies
Healthcare provider profile · identity verified
Keith A Scott, MD
Allopathic & Osteopathic Physicians|Family Medicine · ABBEVILLE, SC · NPI 1740280718
Verified facts
What the public records show
CMS Open Payments records show Keith A Scott, MD received $495.66 in general payments during 2025 across 22 reported records.
ARGENX US, INC. accounted for 13.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $65.92 | 13.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $64.89 | 13.1% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $53.70 | 10.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $51.91 | 10.5% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $42.95 | 8.7% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $32.11 | 6.5% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $29.15 | 5.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $22.32 | 4.5% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $20.04 | 4.0% | 1 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.75 | 3.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.32 | 3.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.09 | 3.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.00 | 3.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.28 | 2.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.24 | 2.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.99 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $495.66 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $65.92 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $64.89 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $53.70 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $51.91 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $42.95 | 2 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $32.11 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $29.15 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $22.32 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 537 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 459 | 96 |
| Potassium Chloride | Potassium Chloride | 452 | 57 |
| Lisinopril | Lisinopril | 404 | 108 |
| Atorvastatin Calcium | Atorvastatin Calcium | 388 | 92 |
| Omeprazole | Omeprazole | 349 | 103 |
| Furosemide | Furosemide | 347 | 60 |
| Trazodone Hcl | Trazodone Hcl | 316 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 309 | 94 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 292 | 78 |
| Meloxicam | Meloxicam | 281 | 77 |
| Losartan Potassium | Losartan Potassium | 265 | 67 |
| Quetiapine Fumarate | Quetiapine Fumarate | 258 | 40 |
| Gabapentin | Gabapentin | 249 | 71 |
| Mirtazapine | Mirtazapine | 240 | 32 |
| Metformin Hcl | Metformin Hcl | 213 | 47 |
| Tramadol Hcl | Tramadol Hcl | 208 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 201 | 39 |
| Sertraline Hcl | Sertraline Hcl | 201 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 194 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 190 | 49 |
| Memantine Hcl | Memantine Hcl | 188 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 185 | 33 |
| Montelukast Sodium | Montelukast Sodium | 183 | 61 |
| Baclofen | Baclofen | 177 | 26 |
| Prednisone | Prednisone | 166 | 111 |
| Clonazepam | Clonazepam | 164 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 147 | 47 |
| Eliquis | Apixaban | 138 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 28 |
| Donepezil Hcl | Donepezil Hcl | 134 | 19 |
| Famotidine | Famotidine | 126 | 34 |
| Divalproex Sodium | Divalproex Sodium | 124 | 12 |
| Metformin Hcl Er | Metformin Hcl | 124 | 29 |
| Xarelto | Rivaroxaban | 106 | suppressed |
| Lorazepam | Lorazepam | 103 | 27 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 102 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 94 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 93 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 19 |
| Diazepam | Diazepam | 89 | 23 |
| Allopurinol | Allopurinol | 84 | 22 |
| Carvedilol | Carvedilol | 81 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 81 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 78 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 18 |
| Ozempic | Semaglutide | 73 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 73 | 53 |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 19 |
| Estradiol | Estradiol | 65 | 22 |
| Risperidone | Risperidone | 65 | suppressed |
| Simvastatin | Simvastatin | 63 | 11 |
| Fluconazole | Fluconazole | 61 | 27 |
| Amoxicillin | Amoxicillin | 60 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 19 |
| Finasteride | Finasteride | 57 | 19 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 57 | 46 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 56 | 12 |
| Trulicity | Dulaglutide | 55 | suppressed |
| Atenolol | Atenolol | 53 | 15 |
| Divalproex Sodium Er | Divalproex Sodium | 53 | suppressed |
| Ondansetron Odt | Ondansetron | 53 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 25 |
| Buspirone Hcl | Buspirone Hcl | 48 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 36 |
| Farxiga | Dapagliflozin Propanediol | 47 | suppressed |
| Glipizide | Glipizide | 47 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 32 |
| Meclizine Hcl | Meclizine Hcl | 44 | 24 |
| Spironolactone | Spironolactone | 42 | 15 |
| Glimepiride | Glimepiride | 41 | 12 |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 39 | suppressed |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Bumetanide | Bumetanide | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 36 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Ketoconazole | Ketoconazole | 34 | suppressed |
| Novolog Flexpen | Insulin Aspart | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 29 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 32 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Fentanyl | Fentanyl | 31 | 11 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | 12 |
| Albuterol Sulfate | Albuterol Sulfate | 29 | 12 |
| Celecoxib | Celecoxib | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 15 |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Cephalexin | Cephalexin | 27 | 16 |
| Dexamethasone | Dexamethasone | 27 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Klor-Con M20 | Potassium Chloride | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 21 |
| Topiramate | Topiramate | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | 16 |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Indapamide | Indapamide | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Levetiracetam Er | Levetiracetam | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 18 |
| Pentasa | Mesalamine | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Nystatin | Nystatin | 18 | 11 |
| Scopolamine | Scopolamine | 18 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Nystop | Nystatin | 16 | 13 |
| Primidone | Primidone | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Nyamyc | Nystatin | 15 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 12 |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Lactulose | Lactulose | 12 | 11 |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $495.66 · 22 records | ARGENX US, INC. | BRIUMVI, Cologuard Collection Kit, ENTRESTO, EVENITY, FLOWTRIEVER, FREESTYLE LIBRE 3, HYQVIA, INJECTAFER, Korlym, LEQVIO, Leqembi, PROLIA, QULIPTA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VYEPTI, VYVGART HYTRULO, XIFAXAN | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error